PURPOSE OF REVIEW: The aim of this review is to sum up the state of the art of urachal carcinoma (UC) in order to easily guide clinicians. RECENT FINDINGS: UC is a rare and aggressive disease with consequent few data about diagnosis and treatment. Dates are mainly based on retrospective trial and case reports with limited prospective trial. Clinical presentation is not specific, often with urinary symptoms. Diagnosis is mainly based on CT scan and MRI, useful to evaluate local invasion and nodal status and to detect the presence of distant metastases. Therefore, biopsy is needed to obtain histological confirmation. Surgery is the gold standard for localized disease, while different chemotherapy schemes have been used in metastatic setting. Novel findings based on mutational analysis of the tumor include the use of biological treatment, such as cetuximab, and immunotherapy, such as atezolizumab, with satisfactory responses, suggesting that personalized treatment could be the most suitable option for UC.
PURPOSE OF REVIEW: The aim of this review is to sum up the state of the art of urachal carcinoma (UC) in order to easily guide clinicians. RECENT FINDINGS:UC is a rare and aggressive disease with consequent few data about diagnosis and treatment. Dates are mainly based on retrospective trial and case reports with limited prospective trial. Clinical presentation is not specific, often with urinary symptoms. Diagnosis is mainly based on CT scan and MRI, useful to evaluate local invasion and nodal status and to detect the presence of distant metastases. Therefore, biopsy is needed to obtain histological confirmation. Surgery is the gold standard for localized disease, while different chemotherapy schemes have been used in metastatic setting. Novel findings based on mutational analysis of the tumor include the use of biological treatment, such as cetuximab, and immunotherapy, such as atezolizumab, with satisfactory responses, suggesting that personalized treatment could be the most suitable option for UC.
Authors: Gladell P Paner; Jesse K McKenney; Güliz A Barkan; Jorge L Yao; Wendy L Frankel; Thomas J Sebo; Steven S Shen; Rafael E Jimenez Journal: Am J Surg Pathol Date: 2011-06 Impact factor: 6.394
Authors: R Torenbeek; J H Lagendijk; P J Van Diest; H Bril; F J van de Molengraft; C J Meijer Journal: Histopathology Date: 1998-01 Impact factor: 5.087
Authors: H Max Bruins; Otto Visser; Martine Ploeg; Christina A Hulsbergen-van de Kaa; Lambertus A L M Kiemeney; J Alfred Witjes Journal: J Urol Date: 2012-08-15 Impact factor: 7.450
Authors: Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger Journal: N Engl J Med Date: 2003-07-17 Impact factor: 91.245
Authors: Moon Jin Kim; Young Sam Kim; Sung Yong Oh; Suee Lee; Young-Jin Choi; Young Mi Seol; Min Jae Park; Ki Hyang Kim; Lee Chun Park; Jung Hun Kang; In-Gyu Hwang; Soon Il Lee; Seung Taek Lim; Hyo Song Kim; Ho Yeong Lim; Sun Young Rha; Hyo-Jin Kim Journal: Korean J Intern Med Date: 2016-04-06 Impact factor: 2.884
Authors: Young Dong Yu; Young Hwii Ko; Jong Wook Kim; Seung Il Jung; Seok Ho Kang; Jinsung Park; Ho Kyung Seo; Hyung Joon Kim; Byong Chang Jeong; Tae-Hwan Kim; Se Young Choi; Jong Kil Nam; Ja Yoon Ku; Kwan Joong Joo; Won Sik Jang; Young Eun Yoon; Seok Joong Yun; Sung-Hoo Hong; Jong Jin Oh Journal: Front Oncol Date: 2021-05-31 Impact factor: 6.244